Business Roundtable
A New Era of Shareholder Activism: Aligning the Interests of All Parties
Wednesday, February 13, 2008
9:30 AM
Park Avenue Suite Center/North
Shareholder activism has been a splinter in the heel of several prominent industry executives, but others maintain that it compels healthy transparency. Increasingly, biotech investors scrutinize spending, challenge corporate decisions, and even design the ouster of top execs. Do activists hinder long-term research efforts, or do they help CEOs realize true company value? Join us to take a look at what happens when an aggressive shareholder buys into a particular company and discuss what this controversial trend may mean for the industry at large.
Moderators
- Annette Grimaldi; Managing Director, Jefferies & Company
Panelists
- Lilian Stern; Principal, Stern Investor Relations, Inc.
- Steve Rouhandeh; Chairman, SCO Financial Group LLC
- Tom McLain; Former Chairman, President and CEO, Nabi Pharmaceuticals